Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginNet MarginOperating MarginReturn on Sales

ENDRA Life Sciences (NDRA) Equity Average (2017 - 2021)

ENDRA Life Sciences (NDRA) has disclosed Equity Average for 5 consecutive years, with $14.1 million as the latest value for Q3 2021.

  • Quarterly Equity Average rose 552.76% to $14.1 million in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $14.1 million through Sep 2021, up 552.76% year-over-year, with the annual reading at $6.0 million for FY2020, 8.37% up from the prior year.
  • Equity Average for Q3 2021 was $14.1 million at ENDRA Life Sciences, down from $16.4 million in the prior quarter.
  • The five-year high for Equity Average was $16.4 million in Q2 2021, with the low at -$1.1 million in Q1 2017.
  • Average Equity Average over 5 years is $5.0 million, with a median of $3.2 million recorded in 2017.
  • The sharpest move saw Equity Average crashed 90.08% in 2018, then soared 838.63% in 2021.
  • Over 5 years, Equity Average stood at $6.2 million in 2017, then crashed by 53.46% to $2.9 million in 2018, then grew by 6.44% to $3.1 million in 2019, then surged by 70.43% to $5.3 million in 2020, then soared by 167.95% to $14.1 million in 2021.
  • According to Business Quant data, Equity Average over the past three periods came in at $14.1 million, $16.4 million, and $12.5 million for Q3 2021, Q2 2021, and Q1 2021 respectively.